Clicky

Prime Medicine, Inc.(PRME)

Description: Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.


Keywords: Biotechnology Life Sciences Emerging Technologies Disease Molecular Biology Medical Genetics Genetic Engineering Gene Editing Technology

Home Page: primemedicine.com

PRME Technical Analysis

21 Erie Street
Cambridge, MA 02139
United States
Phone: 617 564 0013


Officers

Name Title
Dr. Keith Michael Gottesdiener M.D., Ph.D. President, CEO, Secretary & Director
Dr. Ann L. Lee Ph.D. Chief Technical Officer
Dr. Jeremy S. Duffield M.D., Ph.D. Chief Scientific Officer
Dr. Andrew Anzalone M.D., Ph.D. Co-Founder & Head of Prime Editing Platform
Dr. David R. Liu Ph.D. Co-Founder & Member of Scientific Advisory Board
Dr. Allan Reine M.D. Chief Financial Officer
Dr. Meredith Goldwasser Senior VP and Head of Strategy & Corporate Operations
Ms. Carman Alenson CPA, M.B.A. Senior VP of Finance & Chief Accounting Officer
Dr. Karen Brown J.D., Ph.D. Senior Vice President of Intellectual Property & Legal Affairs
Ms. Niamh Alix Chief Human Resources Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.0833
Price-to-Sales TTM: 518.0849
IPO Date: 2022-10-20
Fiscal Year End: December
Full Time Employees: 234
Back to stocks